Journal
Frontiers in Oncology
Publication Date
1-1-2020
Volume
10
First Page
569715
Document Type
Open Access Publication
DOI
10.3389/fonc.2020.569715
Rights and Permissions
Morgensztern D, Dols MC, Ponce Aix S, Postmus PE, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Govindan R and Ong TJ (2021) nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). Front. Oncol. 10:569715. doi: 10.3389/fonc.2020.569715 © 2021 Morgensztern, Dols, Ponce Aix, Postmus, Bennouna, Fischer, Juan-Vidal, Stewart, Ardizzoni, Bhore, Wolfsteiner, Reck, Talbot, Govindan and Ong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Recommended Citation
Morgensztern, Daniel; Dols, Manuel Cobo; Ponce Aix, Santiago; Postmus, Pieter E; Bennouna, Jaafar; Fischer, Jürgen R; Juan-Vidal, Oscar; Stewart, David J; Ardizzoni, Andrea; Bhore, Rafia; Wolfsteiner, Marianne; Reck, Martin; Talbot, Denis; Govindan, Ramaswamy; and Ong, Teng Jin, "nab-paclitaxel plus durvalumab in patients with previously treated advanced stage non-small cell lung cancer (ABOUND.2L+)." Frontiers in Oncology. 10, 569715 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/11310
